Designing PROTACs against enteroviral 2A protease via cereblon E3 ligase recruitment
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Enteroviruses (EV) such as EV-A71 and EV-D68 pose growing public health threats, particularly among children [1-2] , due to their association with severe neurological and respiratory illnesses, including hand, foot, and mouth disease (HFMD) [3-4] and acute flaccid myelitis (AFM) [5][6].Despite their clinical significance, no targeted antiviral therapies currently exist.This project aims to address this gap by applying targeted protein degradation strategies to eliminate 2A protease (2A pro ), a viral enzyme essential for replication and immune evasion.EV 2A pro mediates viral polyprotein processing, suppresses host translation by cleaving eIF4G, and disrupts type I interferon signaling via degradation of IFNAR1 and cleavage of .Its essential role in viral pathogenesis makes it a high-priority antiviral target.To overcome the limitations of conventional inhibitors, we propose the development of proteolysis-targeting chimeras (PROTACs) that direct 2A pro to cereblon (CRBN)-mediated ubiquitination and proteasomal degradation [9-10].PROTACs offer distinct advantages, including catalytic activity, degradation of the entire protein, reduced susceptibility to resistance, and the ability to target structurally challenging proteins [9,11].Using integrative structural biology approaches such as Xray crystallography and crosslinking mass spectrometry, we will rationally design and optimize CRBN-recruiting PROTACs to achieve selective and sustained 2A pro degradation.To enable biochemical and structural characterization of 2A pro , we established an optimized recombinant expression system in E. coli, using solubility-enhancing fusion tags and buffer screening to improve protein yield and purity.Affinity and sizeexclusion chromatography workflows were tailored to obtain milligram quantities of active, monodisperse protein suitable for downstream structural studies and PROTAC binding assays.This research builds on the PANVIPREP consortium's vision for broad-spectrum antiviral development and represents a transformative shift in antiviral strategy-from enzymatic inhibition to targeted degradation.By establishing a scalable platform for degrader-based therapeutics, this project aims to deliver novel and effective antiviral candidates against enteroviruses and potentially other RNA viruses of epidemic and pandemic concern.
Fields of Study & Subjects
Protein Degradation and Inhibitors
Enzyme Structure and Function
Chemical Synthesis and Analysis
Publication details
- Journal / source
- Acta Crystallographica Section A Foundations and Advances
- Volume
- 81
- Issue
- a1
- Pages
- e281–e282
- Publication date
- 30 March 2026
- Language
- EN